This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actelion Pharmaceuticals Ltd.
Drug Names(s): ACT 840, ACT840, ACT 451840, ACT-451840, ACT451840
ACT-840 (ACT-451840) is under development by Actelion, as an oral suspension for the treatment of malaria at early Plasmodium falciparum blood stage infection.
In preclinical studies, ACT-451840 proved to be highly effective against Plasmodium falciparum and Plasmodium vivax. It has also activity against parasites that have developed resistance against current standard therapies. ACT-451840 appears to have a mode of action distinct from current antimalarial drugs, including artemisinins and quinolones. The drug has a rapid onset of action, no erythrocytic stage specificity, and shows reduction of gametocyte infectivity.
Additional information available to subscribers only: